HONG KONG, China — As U.S. markets reopen for the first time since regulators halted downloads of China’s leading ride-hailing app due to bad data practices, Didi Global’s stock is expected to plummet, eliminating billions of dollars from its market value only days after its $4.4 billion IPO. In premarket trading ahead of Tuesday’s reopening of the New York Stock Exchange after the July 4 holiday weekend, Didi stock fell as much as 28% below Friday’s closing price, while two other freshly listed Chinese companies singled out by the regulator also fell. Didi’s stock has dropped by 20%, implying a market value loss of $20 billion. Didi was trading at $12.52 in New York at 6:57 a.m., down 19.4 percent from its IPO price of $14 last week. After deciding that Didi had illegally handled customers’ personal data, China’s Cyberspace Administration (CAC) ordered smartphone app retailers to stop distributing the company’s service on Sunday. Didi’s stock dropped 5% to $15.53 in New York on Friday after the CAC announced its investigation, giving the business a market valuation of over $74 billion. After the CAC cited both companies on Monday, ordering them to halt new user registrations, Kanzhun, the operator of online recruitment app Boss Zhipin, and logistics company Full Truck Alliance, both of which listed last month in the United States, were 9.7% and 15.9% lower in premarket trading, respectively. The assault on companies that recently went public in the United States comes amid a geopolitical battle between Beijing and Washington over technology. The CAC inquiry will harm the three companies’ revenues and profits, as they are heavily reliant on the Chinese market. “It’s a significant warning flag for investors, since no Chinese firm appears to be immune to Chinese regulatory scrutiny,” said Zennon Kapron, managing director of Singapore-based consultancy Kapronasia. “This was a risk that could have been overlooked in the past, but not any longer.” Although LinkDoc Technology, a medical data business backed by Alibaba Health Information Technology, is on track to raise up to $210 million in an IPO expected to price on Thursday, it might delay the push by Chinese companies to list in the United States. According to a source close to the deal, the offering has sparked “investor interest.” According to statistics from research firm Dealogic, 34 Chinese businesses raised $12.4 billion in New York floats in the first half of 2021, compared to 18 listings that garnered $2.8 billion in the same period last year. Price of a share “Performance does important,” according to one IPO banker in Hong Kong. “The opening of the shares will have an impact on the pipeline in the near future. In a climate where U.S.-listed Chinese companies are being targeted, common logic dictates that the IPO flow will begin to shift to Hong Kong.” The CAC’s investigations are part of a months-long campaign by Chinese regulators on technology businesses. Authorities have looked into antitrust violations, data security, and privacy concerns in an attempt to rein in technology companies’ and their wealthy founders’ rising power. Alibaba Group Holding and its financial partner Ant Group have been at the forefront of the crackdown. Last November, officials tightened regulations on Ant’s lending operations, preventing it from launching what was believed to be the world’s largest IPO. Meanwhile, Alibaba was fined a record 18.2 billion yuan ($2.75 billion) for anti-competitive acts in April. More than 30 other Chinese enterprises, including food delivery service Meituan, internet giant Tencent, and online retailer JD.com, have been subjected to increased regulatory scrutiny./n
Read More
